



# Best Available Copy

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: I. Reid

Application No.: 10/016,371

Art Unit: 1617

Filed: December 10, 2001

Examiner: S. Jiang

Title: A METHOD OF ADMINISTERING  
CALCIUM CITRATE

### 1.132 DECLARATION OF IAN R. REID

1. I, Ian R. Reid, do hereby declare and state the following:
2. I am a medical doctor, having earned my medical degree in 1978 from the University of Auckland (New Zealand). I have been active in the area of calcium research for 25 years. My curriculum vitae is attached.
3. I am the inventor of, and have read the above-captioned patent application, as well as the Examiner's Actions and responses.
4. U.S. Patent 4,851,221 of Pak et al. ("Pak") is cited by the Examiner in this case. The Pak patent does not discuss the use of calcium citrate supplementation for increasing HDL levels in plasma in a postmenopausal woman or for increasing the ratio of HDL to LDL in a postmenopausal woman. The Pak patent is not concerned with same problems that are addressed in the present application.
5. The article of Mitchell et al., "Effect of Oral Calcium on Cholesterol Metabolism", *J. Atheroscler. Res.*, 1968, 8: 913-922, ("Mitchell") was also cited by the examiner. Mitchell is concerned with cholesterol and triglyceride levels and the effect of calcium supplementation thereon. However, the data presented in the Mitchell article is for supplementation using calcium glycerophosphate and calcium gluconolactogluconate. Data is not provided for calcium citrate. Importantly, Mitchell concludes that any benefit on cholesterol and triglyceride levels from supplementation with calcium glycerophosphate and calcium gluconolactogluconate

## Best Available Copy

is minor at best. In the abstract, the authors note that “[t]he serum cholesterol and triglyceride levels showed little change from basal levels during calcium supplementation periods.” Also, at page 921, at the beginning of the third full paragraph, Mitchell notes, “[t]he changes in serum cholesterol and triglyceride levels were not significant.” Thus, not only did Mitchell use a different calcium salt than that used in the pending application, Mitchell saw no significant benefits on serum cholesterol and triglyceride levels. Mitchell et al did not assess HDL and LDL levels in their subjects, and it is changes in these components of serum cholesterol which are the subject of the claims in the present patent application.

6. The Nutrition Reviews article entitled “Calcium and Serum Cholesterol”, *Nut. Rev.*, 1967, 25: 298-300, (“Nutrition Reviews”) is also cited by the examiner. Nutrition Reviews is concerned with serum cholesterol levels and the effect of calcium supplementation thereon. Nutrition Reviews notes that any positive effects of calcium supplementation on serum cholesterol are not maintained for longer than three to four weeks. The abstract of Nutrition Reviews notes that:

A hypocholesteremic effect of oral calcium, supplements seems to occur only in subjects with raised serum cholesterol. There is no evidence that this effect is maintained for longer than three to four weeks, and there seems to be no justification for using oral calcium as a means for reducing serum cholesterol levels.

In the final paragraph at page 300, Nutrition Reviews states:

The exact mechanism of the hypocholesteremic effect of calcium is unclear. Oral calcium supplements result in an increase in fecal fat excretion and excretion of fatty acids as calcium soaps, and may interfere with absorption of cholesterol. The available evidence suggests that the cholesterol lowering effect of calcium supplements occurs only in subjects with a raised serum cholesterol and there is no proof that this effect is more than transient. On the evidence available, bearing in mind the risks of a prolonged high dosage calcium ingestion, there seems to be no justification for recommending oral calcium supplements as a means of reducing serum cholesterol.

## Best Available Copy

7. Clearly, Nutrition Reviews instructs that calcium supplementation is not effective as a means of reducing serum cholesterol, and it does not address effects of calcium on LDL and HDL sub-fractions of cholesterol.
8. Despite what is taught in the above-referenced patent and journal articles, I have found that calcium citrate supplementation is useful in decreasing serum LDL levels, increasing serum HDL levels, and improving the HDL/LDL ratio.
9. In the original application, data was presented showing a 7.3% increase in HDL, a 7.8% decrease in LDL, a decrease in total cholesterol of 3.7%, and an increase of 17.7 % in HDL/LDL ratio over a twelve month period (see specification at page 18-19, paragraph [0072]. Also in the original application, Figures 1A, 1B, and 2B provide data to 12 months of supplementation with calcium citrate. We now have results indicating that this improvement is maintained at least until 4 years. This data is appended to this declaration. This data clearly represents unexpected results in view of the cited prior art, which discusses only modest improvements in serum cholesterol at best, and further the benefits described in the prior art are described therein as very short-term relative to both the results described in the application and further supported by the data provided currently.
10. This new data further supports what is already supported in the original application; i.e., that calcium citrate supplementation has a significant effect on serum cholesterol. This new four-year data is clearly contrary to the teachings of Nutrition Reviews, insofar as calcium supplementation is concerned. It is also contrary to the teachings of Mitchell which show little change in the serum cholesterol and triglyceride levels from basal levels during calcium supplementation with calcium glycerophosphate and calcium gluconolactogluconate. The reference of Pak is not relevant to the issue, as Pak is not directed to the use of calcium citrate supplementation for increasing HDL levels in plasma in a postmenopausal woman or for increasing the ratio of HDL to LDL in a postmenopausal woman.

## Best Available Copy




11. Based on these observations, the cited prior art of Pak, Mitchell, or Nutrition Reviews, either alone or when considered in light of each other, would disclose or suggest the treatments claimed in the pending application.
12. I hereby declare that all statements made herein on my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Title 18, § 1001 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

August 22, 2005

Date



Ian R. Reid





## CURRICULUM VITAE

## Ian Reginald Reid

**Date of Birth :** 23 April 1954

**Qualifications:** B.Sc. Human Biology, University of Auckland, 1975.  
M.B.Ch.B. University of Auckland, 1978.  
F.R.A.C.P. 1985  
M.D., University of Auckland, 1989.

## **Honours/Prizes**

1971 New Zealand University Junior Scholarship.

1973 Annual prize in Human Biology. }

1974 Senior prize in Human Biology. }

Eric Hector Goodfellow Memorial Prize. }

1976 Ciba-Geigy prize in Pharmacology. }

College of General Practitioners Prize. } Awarded by the

1977 W.W. Phillips Scholarship. }

Douglas Robb Prize. }

H.B. Turbott Prize. }

Senior Scholarship in Medicine. }

1984 Ruth Spencer Memorial Fellowship - awarded by the Auckland Medical Research Foundation

1985 New Zealand Endocrine Society Young Investigator's Prize.

New Zealand Medical Research Council Overseas Fellowship.

1997 Fellowship of the Royal Society of New Zealand

2002 Achievement Award, Medical and Health Sciences Chapter, Alumni Association, University of Auckland

2003 Elected to Membership of the Association of Osteobiology

## Appointments

1978 House Surgeon Wellington Hospital Board.

1979-80 Senior House Officer, Norfolk and Norwich Hospital, Norwich, England.

1981 Medical Registrar, Auckland Hospital, (Professor J.D.K. North).

1982-83 Registrar Department of Endocrinology, Auckland Hospital, (Professor H.K. Ibbertson).

1984-5 Ruth Spencer Medical Research Fellow, Department of Endocrinology, University of Auckland (Professor H.K. Ibbertson).

1985-87 Research Fellow, Division of Bone & Mineral Metabolism, Washington University School of Medicine, St Louis, USA, (Professor L.V. Avioli).

1987-90 Senior Lecturer in Medicine, University of Auckland, New Zealand.

1990-98 Associate Professor in Medicine, University of Auckland.

1998- 9 Deputy Head, Department of Medicine, University of Auckland.

1998- Professor of Medicine & Endocrinology, University of Auckland.

1999- Head, Department of Medicine, University of Auckland.

### **Invited Lectureships**

1987 Consensus Development Conference, National Osteoporosis Society of UK, London.

1988 Royal North Shore Hospital, Sydney and Repatriation General Hospital, Concord, Australia.

1990 Sydney Bone Symposium, Sydney.

Australian and New Zealand Rheumatism Association Biennial Scientific Meeting, Queenstown, New Zealand.

1991 American Society for Bone and Mineral Research, Clinical Day, San Diego.

Australia and New Zealand Bone and Mineral Society Annual Scientific Meeting, Sydney.

International Conference on Osteoporosis, Kobe, Japan.

NZ Annual Scientific Meeting, Royal Australasian College of Physicians, Dunedin.

1992 Member of Scientific Committee and invited speaker, First International Symposium on Osteoporosis, Beijing.

Endocrine Society Annual Scientific Meeting, San Antonio.

Society for Endocrinology, Metabolism and Diabetes in Southern Africa, Durban.

New Zealand Geriatrics Society and Royal Australasian College of Physicians, Palmerston Nth.

Nutrition Society of New Zealand Conference, Palmerston Nth.

1993 Endocrine Society of Australia Annual Scientific Meeting, Dunedin.

1994 New Zealand Society of Endocrinology Annual Scientific Meeting, Wellington.

New Zealand Association of Natural Family Planning Annual Conference, Nelson.

Mineralised Tissue Society of Western Australia, Royal Perth Hospital and Sir Charles Gairdner Hospital, Perth.

1995 International Satellite Meeting on Steroids and Bone, Queensland.

2nd International Symposium on Paget's Disease of Bone, Sydney.

3rd Annual National Medico-Legal Conference, Wellington.

Combined Australian and New Zealand Rheumatology Associations Scientific Meeting, Auckland

Waikato Hospital, Hamilton, New Zealand.

1996 German Cancer Congress, Berlin.

Royal Adelaide, Queen Elizabeth, and Lyell McEwin Hospitals, Adelaide.

International Congress of Endocrinology, San Francisco.

Annual Scientific Meeting, Endocrine Society of Australia, Sydney, September, 1996.

First World Congress on Calcium and Vitamin D in Human Life (organised by the Food and Agricultural Organisation of the United Nations), Rome.

Australian National Consensus Conference: The Prevention and Management of Osteoporosis, Canberra.

1997 Waikato Hospital, Hamilton, New Zealand.

Annual Scientific Meeting, Royal Australasian College of Physicians, Auckland.

Second International Conference on Osteoporosis, Osaka.

1998 Royal Australasian College of Pathologists Clinical Biochemistry Education Week, Auckland.

International Society for Clinical Densitometry, Hawaii.

Division of Endocrinology, Mayo Clinic, Rochester

Fundacion Argentina de Osteologia, Buenos Aires

Division of Endocrinology, University of Connecticut Health Center, Farmington

Wakefield Hospital, Wellington

Australasian Menopause Society, Annual Scientific Meeting, Auckland

23rd Congresso Brasileiro de Endocrinologia e Metabologia, Sao Paulo

2nd Joint Meeting of the American Society of Bone and Mineral Research and the International Bone and Mineral Society, San Francisco

International Bone Forum, Yokohama

1999 Bones and Health Conference, Dunedin

Royal Australasian College of Surgeons Annual Scientific Meeting, Auckland

Scientific Committee Member, 3rd International Congress on Osteoporosis, Xian, China

Endocrine Society of Australia Workshop, Adelaide

Annual Scientific Meeting, New Zealand Society of Endocrinology

Diet, Health and Bones Symposium, New Zealand Dairy Research Institute

Royal Brisbane Hospital

Glucocorticoid Hormone Action in Rheumatic Autoimmune Diseases, Bad Nauheim, Germany

Asian Pacific Osteoporosis Foundation, Inaugural Meeting, Hong Kong

2000      Plenary Lecturer, World Congress on Osteoporosis, Chicago  
            International Scientific Advisory Committee and Plenary Lecturer,  
            International Society for Clinical Densitometry, Rio de Janeiro  
            Annual Scientific Meeting, Osteoporosis Society of the Phillipines, Manilla  
            Malaysian Osteoporosis Society, Kuala Lumpur  
            International Congress of Endocrinology, Sydney  
            International Bone Meeting, Hamilton Island, Australia

2001      Osteoporosis Society of Singapore, Singapore  
            Indonesian Osteoporosis Society, Jakarta  
            Annual Scientific Meeting, American Society for Bone and Mineral Research  
            Annual Scientific Meeting, Australia and New Zealand Bone and Mineral  
            Society  
            Royal College of Orthopaedic Surgeons of Thailand, Bangkok  
            Taiwan Osteoporosis Society, Taipei  
            Osteoporosis New Zealand Bone Densitometry Workshop, Auckland  
            Regional Osteoporosis Symposium and Certificate Course, Hong Kong  
            Royal Australasian College of Physicians Annual Scientific Meeting,  
            Auckland  
            College of Pharmacists OMRO Symposium, Wellington  
            South Australia Endocrinology Weekend, Clare Valley

2002      International Osteoporosis Symposium, Riyad  
            Frontiers of Skeletal Biology Conference, Davos  
            International Osteoporosis Symposium, Honolulu  
            Endocrine Society Annual Scientific Meeting, San Francisco  
            Australian Rheumatology Association and New Zealand Rheumatology  
            Association Joint Meeting, Christchurch

Royal Society of New Zealand, Canterbury Branch

Regional Osteoporosis Symposium and Certificate Course, Hong Kong

Functional Foods for Health and Profit, Auckland

NZ Gastroenterological Society , Annual Scientific Meeting, Auckland

8<sup>th</sup> International Pacific Rim Biotechnology Conference, Auckland

2003 Osteoporosis Symposium, Hong Kong

Annual Scientific Meeting, Royal Australasian College of Physicians, Hobart

Annual Scientific Meeting, Australia and New Zealand Bone and Mineral Society, Coolum, Australia

Chair, Scientific Program Committee, International Bone and Mineral Society Biennial Meeting, Osaka

NZRA/RACP/IMSANZ Meeting, Rotorua

17th Annual Meeting of Metabolic Bone Disease Society of Colorado, Denver

Malaysian Osteoporosis Society, Penang

Advances in Skeletal Medicine Course, Perth

2004 Australian Society for Geriatric Medicine Annual Scientific Meeting, Perth

Australia and New Zealand Nuclear Medicine Society Annual Scientific Meeting, Wellington

Annual NZ Renal Physicians & Transplant Surgeons Conference, Auckland

Osteoporosis New Zealand Bone Densitometry Workshop, Wellington

VIII World Congress on Clinical Pharmacology and Therapeutics, Brisbane

International Congress on Clinical Nutrition, Brisbane

Sociedad Argentina de Osteoporosis Annual Scientific Meeting, Buenos Aires

Australia and New Zealand Bone and Mineral Society, Annual Scientific Meeting, Sydney

Australasian Society for Parenteral and Enteral Nutrition, Annual Scientific Meeting, Auckland

New Zealand Nutrition Foundation, Annual General Meeting, Auckland

2005                   3<sup>rd</sup> International Conference on Children's Bone Health, Sorrento

Australian Rheumatology Association, Annual Scientific Meeting, Melbourne

Advances in the Molecular Pharmacology and Therapeutics of Bone Disease, Oxford

Osteoporosis Australia Vitamin D and Calcium Forum, Melbourne

### **Committee Appointments**

1988-90           Foundation Council Member, Australia and New Zealand Bone and Mineral Society.

1988-90           Member, Auckland Hospital Research Ethics Committee.

1990-5           Member, Auckland Area Health Board Ethics Committee.

1990           Member, NZ Department of Health Working Party on Osteoporosis.

1991-3           Member, Assessing Panel, Health Research Council of New Zealand.

1992-8           Member, Biomedical Research Committee, Health Research Council of New Zealand.

1993-           Member, Scientific Advisory Committee, New Zealand Nutrition Foundation.

1993-4           Vice-President, Australia and New Zealand Bone and Mineral Society.

1993-4           Member, Health Research Council Working Party on Clinical Research.

1993-9           Chairman, Assessing Committees, Health Research Council of New Zealand.

1995-7           President, Australia and New Zealand Bone and Mineral Society

1996-8           Founding Councillor, World Federation on Osteoporosis

1996-7 Member, Clinical Research Committee, Health Research Council of New Zealand.

1997-9 Member, Data Monitoring Safety Board, Health Research Council of New Zealand.

1998 Member, Scientific Program Committee, American Bone and Mineral Society-International Bone and Mineral Society 2nd Joint Meeting

1998-2000 Member, Assessing Panel, Marsden Fund, Royal Society of New Zealand

1998-2002 Member, Medical and Health Science Fellowship Selection Panel, Royal Society of New Zealand. Chair, 2002.

1998- Team Leader, WHO Osteoporosis Initiative

1998- Member, Board of Directors, International Bone and Mineral Society

1998-2002 Founding Board Member, Osteoporosis New Zealand

1999- Founding Councillor and Secretary, Asian Pacific Osteoporosis Foundation

1999- Member, Advisory Medical Panel, The Paget Foundation, New York

1999-2002 Founding Chairperson, Scientific Committee, Osteoporosis New Zealand

1999- Member, National Health Committee on Hormone Replacement Therapy

1999-2003 Secretary-Treasurer, International Bone and Mineral Society

1999- Member, Committee of Scientific Advisors of the International Osteoporosis Federation

2000- Board of Studies, Undergraduate Medicine, University of Auckland

2001- Member, Advisory Committee, Centre for Osteoporosis Care and Control, Hong Kong

2002- Board Member, Lactopharma Joint Venture

2003- Faculty Staffing Committee, Medicine and Health Sciences, University of Auckland

2003 Member of the Medicine and Public Health Peer Review Panel, Performance Based Research Fund, NZ Government

2003-2005 President-Elect, International Bone and Mineral Society

2005 Chair, Australian Medical Council Accreditation Team, University of Queensland

2005- President, International Bone and Mineral Society

2005-6 Member of the Medicine and Public Health Peer Review Panel, Performance Based Research Fund, NZ Government

### **Peer Review Activities**

#### Editorial Board Memberships

Journal of Clinical Endocrinology and Metabolism

Osteoporosis International

Bone

New Ethicals Patient Management

New Zealand Medical Journal (1998-2003)

BoneKEy

Journal of Clinical Densitometry

Consultant Editor, European Journal of Experimental Musculoskeletal Research.

*Referee for:* American Journal of Medicine, American Journal of Obstetrics and Gynecology, American Journal of Physiology, Archives of Oral Biology, Archives of Dermatology, Australia and New Zealand Journal of Medicine, Bone, British Medical Journal, Calcified Tissue International, Clinical Endocrinology (Oxford), Diabetes Care, Diabetic Medicine, Drugs, Endocrine Practice, Endocrinology, European Journal of Clinical Investigation, European Journal of Endocrinology, Journal of the American Medical Association, Journal of Bone and Mineral Research, Journal of Clinical Endocrinology and Metabolism, Journal of Internal Medicine, Journal of Laboratory and Clinical Medicine, Journal of Rheumatology, Lancet, Maturitas, New Zealand Medical Journal, Osteoporosis International, Science, World Journal of Surgery, and for research funding organisations in New Zealand and Australia.

### **Current Research Funding**

Programme Grant from the Health Research Council of New Zealand

Foundation of Research, Science and Technology

Fonterra Ltd

Commercial contracts with pharmaceutical companies

**Patents**

- 1 Reid IR, Martin TJ. Effects of leukemia inhibitory factor on bone.
- 2 Cornish J, Reid IR, Martin TJ. Osteostatin - bone growth effects
- 3 Reid IR, Cornish J, Cooper GJS. Amylin - Therapeutic Method and Compounds of use Therein  
PCT application PCT/NZ95/00062 based on NZ filing 260995 13 July 1994  
Granted: USA Patent Number: 5922677
4. Reid IR, Cornish J, Cooper GJS, Coy DH. Treatment of Bone Disorders with Adrenomedullin  
USA patent application 08/634 562 - filed in USA on 18 April 1996  
Completed: PCT/US97/06365  
Granted: USA Patent Number: 5,888,963  
Pending: Australian Patent Number: 724775  
Pending: Canada Application Number: 2,252,228  
Pending: Europe: Application number: 97918682.2  
Pending: Japan: Application number: 537359/97
5. Cornish J, Reid IR, Cooper GJS  
Treatment of Bone Disorders with Adrenomedullin or Adrenomedullin Agonists  
Filed 30 March 1999  
PCT application PCT/NZ00/00038 Completed  
Provisional USA Patent Number: 09/280,501  
Granted: USA Patent Number 6,440,421 B1, Aug 27, 2002  
Canada Pending: Number Unknown  
Australia Pending: 33384/00  
Europe Pending: 0911518.9  
Japan Pending: 2000-608047
6. Reid IR, Cornish J, Cooper, GJS, Coy DH  
Amylin Fragments - Compounds and uses thereof (1-8) in Bone Disorders  
USA patent application - filed in USA on 18 September 1997  
Pending: USA Patent Number: 08/933,452  
Granted: USA Patent Number 6,821,954 B2, Nov 23, 2004  
PCT: W09916406  
Pending in Australia, Japan, Canada and Europe
7. Reid IR, Cornish J, Cooper GJS. Amylin and Adrenomedullin - Effects on Chondrocytes and Cartilage  
PCT filed on 26 September 1997  
Completed: PCT/NZ98/00145  
Completed Provisional NZ Patent Number: 328853  
Issued: USA Patent No. 6,869,926 B1, 22 March 2005.  
Pending European Patent Number: 98946738.6  
Pending Japanese Patent Number: 513546/2000

8. Cornish J, Reid IR, Palmano KP, Haggarty NW.  
Milk protein antiresorber.  
NZ Provisional lodged 2001
9. Reid IR . A method of administering calcium citrate.  
US Provisional application lodged November, 2001.
10. Cornish J, Reid I R, Palmano K, Haggarty N W. Lactoferrin.  
New Zealand Provisional patent application NZ518121 filed 3 April, 2002; US application 10/205,960 filed 26 July, 2002 and PCT application NZ02/00137 filed 29th July, 2002.
11. Reid I R, Cornish J, Naot D, Grey A B. LDL: Receptor related proteins 1 and 2.  
US application 60/380,227 filed May 13, 2002, incorporated into PCT application NZ03/00087 filed 13 May, 2003.
12. Cornish J, Reid I R, Naot D, Palmano K and Grey A B. LDL Receptor related proteins 1 and 2 and treatment of bone and cartilage conditions. US provisional application US 60/463,419 of 16 April, 2003, incorporated into PCT application NZ03/00087 filed 13 May, 2003.
13. Cornish J, Reid IR, Cooper GJS, Buchanan CM. Preptin Methods of Use.  
Filed 1 August 2002  
Provisional USA Patent Number: 08987-007P01
14. Cornish J, Reid IR, Jian-ming Lin  
Effect of fibroblast growth factor-8a (FGF-8a) on osteoblast and osteoclast proliferation, differentiation and function  
US Provisional application lodged 4 October, 2002

## Publications

Total Number: 291 (excluding abstracts)

### Refereed Journal Articles

1. Eade MN, Reid IR, Quinn JP. Intestinal blood flow in the dog measured by indicator fractionation without tissue sampling. **Clin Exp Pharmacol Physiol** 1977; 4: 235-245.
2. Reid IR. The use of iatrogenic hypothyroidism in the treatment of intractable angina. **NZ Med J** 1983; 96: 285-286.
3. Reid IR, Wallis WE. The chronic and severe forms of eosinophilic meningitis. **Aust NZ J Med** 1984; 14: 163-165.
4. Baker JR, Reid IR, Holdaway IM. Serum fructosamine in patients with diabetes mellitus. **NZ J Med** 1985; 98: 532-5.
5. Reid IR. Transient hypercalcaemia following aspirin overdose. **Aust NZ J Med** 1985; 15: 364.
6. Reid IR, France JT, Pybus J, Ibbertson HK. Low plasma testosterone levels in glucocorticoid-treated male asthmatics. **BMJ** 1985; 291: 574.
7. Reid IR, Gallagher DJA, Bosworth J. Prophylaxis against vitamin D deficiency in the elderly by regular sunlight exposure. **Age Ageing** 1986; 15: 35-40.
8. Reid IR, Chapman GE, Fraser TRC, Davies AD, Surus AS, Meyer J, Huq NL, Ibbertson HK. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. **J Clin Endocrinol Metab** 1986; 62: 379-383.
9. Reid IR, Katz J, Ibbertson HK, Gray DH. The effects of hydrocortisone, parathyroid hormone and the bisphosphonate APD on bone resorption in neonatal mouse calvaria. **Calcif Tissue Int** 1986; 38: 38-43.
10. Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. **Am J Clin Nutr** 1986; 44: 287-290.
11. Reid IR, Schooler BA, Hannon S, Ibbertson HK. The acute biochemical effects of four proprietary calcium supplements. **Aust NZ J Med** 1986; 16: 193-197.
12. Reid IR, Pybus J, Lim TMT, Hannon S, Ibbertson HK. The assessment of intestinal calcium absorption using stable strontium. **Calcif Tissue Int** 1986; 38: 303-305.
13. Reid IR, Mackie M, Ibbertson HK. Bone mineral content in Polynesian and white New Zealand women. **BMJ** 1986; 292: 1547-1548.

14. Reid IR, Civitelli R, Westbrook SL, Avioli LV, Hruska KA. Cytoplasmic pH regulation in canine renal proximal tubule cells. **Kidney Int** 1987; 31: 1113-1120.
15. Civitelli R, Reid IR, Halstead LR, Avioli LV, Hruska KA. Membrane potential and cation content of osteoblast-like cells (UMR 106) assessed by fluorescent dyes. **J Cell Physiol** 1987; 131: 434-441.
16. Reid IR, Teitelbaum SL, Dusso A, Whyte MP. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia: effect of successful tumor resection on mineral homeostasis. **Am J Med** 1987; 83: 350-354.
17. Reid IR, Civitelli R, Halstead LR, Avioli LV, Hruska KA. Parathyroid hormone acutely elevates intracellular calcium in osteoblast-like cells. **Am J Physiol** 1987; 253: E45-E51.
18. Reid IR, Ibbertson HK. Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. **Hormone Res** 1987; 27: 200-204.
19. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). **Lancet** 1988; i: 143-146.
20. Reid IR, Civitelli R, Avioli LV, Hruska KA. Parathyroid hormone depresses cytosolic pH and DNA synthesis in osteoblast-like cells. **Am J Physiol** 1988; 255: E9-E15.
21. Sugimoto T, Ritter C, Reid IR, Morrissey J, Slatopolsky E. Effect of 1,25(OH)<sub>2</sub>D<sub>3</sub> on cytosolic calcium in dispersed parathyroid cells. **Kidney Int** 1988; 33: 850-854.
22. Civitelli R, Reid IR, Westbrook S, Avioli LV, Hruska KA. Parathyroid hormone elevates inositol polyphosphates and diacylglycerol in a rat osteoblast-like cell line. **Am J Physiol** 1988; 255: E660-E667.
23. Levy J, Reid IR, Halstead L, Avioli LV. Abnormal cell calcium concentrations in cultured bone cells obtained from femurs of obese and non-insulin-dependent diabetic rats. **Calcif Tissue Int** 1989; 44: 131-137.
24. Reid IR, Pathogenesis and treatment of steroid osteoporosis. **Clin Endocrinol** 1989; 30: 83-103.
25. Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP. X-linked hypophosphatemia in adults, prevalence of skeletal radiographic and scintigraphic features. **Radiology** 1989; 171: 403-414.
26. Reid IR, Gluckman PD, Ibbertson HK. Insulin-like growth factor 1 and bone turnover in glucocorticoid-treated and control subjects. **Clin Endocrinol** 1989; 30: 347-353.
27. Suzuki Y, Hruska KA, Reid IR, Alvarez UH, Avioli LV. Characterization of

phospholipase C activity of the plasma membrane and cytosol of an osteoblast-like cell line. **Am J Med Sci** 1989; 297: 135-144.

28. Fenton AJ, King AR, Reid IR. Hypercalcemia and squamous cell carcinoma complicating chronic osteomyelitis. **Aust NZ J Med** 1989; 19: 358-361.
29. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphataemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. **Medicine (Baltimore)** 1989; 68: 336-352.
30. Reid IR, Lowe C, Cornish J, Skinner SJM, Hilton DJ, Willson TA, Gearing DP, Martin TJ. Leukemia inhibitory factor, a novel bone-active cytokine. **Endocrinology** 1990; 126: 1416-1420.
31. Reid IR, Lowe C, Cornish J, Gray DH, Skinner SJM. Adenylate cyclase blockers dissociate PTH-stimulated bone resorption from cAMP production. **Am J Physiol** 1990; 258: E708 - E714.
32. Reid IR, Schooler BA, Stewart AW. Prevention of glucocorticoid induced osteoporosis. **J Bone Mineral Res** 1990; 5: 619-623.
33. Reid IR, Cullen S, Schooler BA, Livingston NE, Evans MC. Calcitropic hormone levels in Polynesians, evidence against their role in inter-racial differences in bone mass. **J Clin Endocrinol Metab** 1990; 70: 1452 - 1456.
34. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. **Arch Int Med** 1990; 150: 2545-2548.
35. Orr-Walker B, Harris R, Holdaway IM, Foote G, Reid IR. High peripheral and axial bone densities in a postmenopausal woman with untreated hypoparathyroidism. **Postgrad Med J** 1990; 66: 1061-1063.
36. Reid IR, Murphy WA, Hardy DC, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography and absorptiometry. **Am J Med** 1991; 90: 63-69.
37. Reid IR, Evans MC, Ames R, Wattie DJ. The influence of osteophytes and aortic calcification on spinal mineral density in postmenopausal women. **J Clin Endocrinol Metab** 1991; 72: 1372-1374.
38. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid I. Reduced bone density in women using depot medroxyprogesterone acetate for contraception. **BMJ** 1991; 303: 13-16.
39. Lowe C, Cornish J, Martin TJ, Reid IR. Effects of leukemia inhibitory factor on bone resorption and DNA synthesis in neonatal mouse calvaria. **Calcif Tissue Int** 1991; 49:394-397

40. Lowe C, Cornish J, Callon K, Martin TJ, Reid IR. Regulation of osteoblast proliferation by leukaemia inhibitory factor. **J Bone Mineral Res** 1991; 6:1277-1283.
41. Lowe C, Gray DH, Reid IR. Serum blocks the osteolytic effect of cortisol in neonatal mouse calvaria. **Calcif Tissue Int** 1992; 50: 189-192.
42. Reid IR, Evans MC, Wattie DJ, Ames R, Cundy TF. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. **Osteoporosis Int** 1992; 2:103-105.
43. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. **Clin Endocrinol** 1992; 36:229-234.
44. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TMT, Cundy TF. Determinants of total body and regional bone mineral density in normal postmenopausal women- a key role for fat mass. **J Clin Endocrinol Metab** 1992; 75:45-51.
45. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. **J Clin Endocrinol Metab** 1992; 75:779-782.
46. Reid IR, Evans MC, Ames R. Relationships between upper arm anthropometry and soft tissue composition in postmenopausal women. **Am J Clin Nutr** 1992; 56:463-6.
47. Reid IR, Wattie DJ, Evans MC, Budayr AA. Post-pregnancy osteoporosis associated with hypercalcaemia: a case report and literature review. **Clin Endocrinol** 1992; 37:298-303.
48. Reid IR, Evans MC, Stapleton J. Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. **J Bone Mineral Res** 1992; 7:1221-5.
49. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. **N Engl J Med** 1993; 328:460-4. Correction- **N Engl J Med** 1993; 329:1281.
50. Cornish J, Callon K, King A, Edgar S, Reid IR. The effect of leukemia inhibitory factor on bone in vivo. **Endocrinology** 1993; 132:1359-1366.
51. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult cystic fibrosis patients. **Thorax** 1993; 48:589-593.
52. Reid IR, Evans MC, Cooper GJS, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. **Am J Physiol** 1993; 265:E655-E659.

53. Reid IR. Benefits, risks and costs of calcium supplementation in postmenopausal women. **PharmacoEconomics** 1994; 5:1-4.
54. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone mineral density after discontinuing depot medroxyprogesterone acetate contraception. **BMJ** 1994; 308:247-8.
55. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. **Clin Endocrinol** 1994; 40:671-677.
56. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD. Determinants of the rate of bone loss in normal postmenopausal women. **J Clin Endocrinol Metab** 1994; 79:950-954.
57. Reid IR, Evans MC, Ames RW. Volumetric bone density of the lumbar spine is related to fat mass but not lean mass in normal postmenopausal women. **Osteoporosis Int** 1994; 4:362-367.
58. Reid IR, Chin K, Evans MC, Jones JG. Relation between increase in length of hip axis in older women between 1950's and 1990's and increase in age-specific rates of hip fracture. **BMJ** 1994; 309:508-509.
59. Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. **Ann Intern Med** 1994; 121:745-749.
60. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. **J Clin Endocrinol Metab** 1994; 79:1595-1599.
61. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women- a randomised controlled trial. **Am J Med** 1995; 98:331-335.
62. Reid IR, Legge M, Stapleton JP, Evans MC, Grey AB. Regular exercise dissociates fat mass and bone density in premenopausal women. **J Clin Endocrinol Metab** 1995; 80: 1764-1768.
63. Reid IR, Mills DAJ, Wattie DJ. Ototoxicity associated with intravenous bisphosphonate administration. **Calcif Tissue Int** 1995; 56: 584-585.
64. Cundy TF, Cornish J, Evans MC, Gamble GD, Stapleton JP, Reid IR. Sources of inter-racial variation in bone mineral density. **J Bone Mineral Res** 1995; 10: 368-373.
65. Cornish J, Callon KE, Cooper GJS, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. **Biochem**

**Biophys Res Comm** 1995; 207:133-139.

66. Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurological sequelae of pagetic spinal stenosis. **Arch Int Med** 1995; 155:1813-1815.
67. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. **J Clin Endocrinol Metab** 1995; 80:3191-3195.
68. Norton R, Butler M, Currie R, Lee-Joe T, Campbell J, Reid IR, Gray H. Hip fracture incidence among older people in Auckland: a population-based study. **NZ Med J** 1995; 108: 426-8.
69. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the anti-estrogen tamoxifen on bone mineral density in normal late postmenopausal women. **Amer J Med** 1995; 99:636-641.
70. Cornish J, Callon KE, Reid IR. An *in vivo* model for the rapid assessment of the local effects of parathyroid hormone on bone histomorphometry. **Bone** 1995; 17 (suppl): 249S- 254S.
71. Cundy T, Farquhar CM, Cornish J, Reid IR. Spinal bone loss in women using high dose oral medroxyprogesterone acetate. **J Clin Endocrinol Metab** 1996; 81:1014-1017.
72. Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. **N Engl J Med** 1995; 333: 1437-1443.
73. Grey AB, Cundy TF, Evans MC, Reid IR. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late postmenopausal women. **Clin Endocrinol** 1996; 44: 293-296.
74. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. **Arch Int Med** 1996; 156:1173-1177.
75. Alendronate Phase III Osteoporosis Treatment Study Group. Oral alendronate induces increases in bone mass of the spine, hip and total body over three years in postmenopausal women with osteoporosis. **Bone** 1996; 18:141-150.
76. Reid IR, Chin K, Evans MC, Cundy T. Longer femoral necks in the young - a predictor of further increases in hip fracture incidence? **NZ Med J** 1996; 109:234-235.
77. Cundy T, Evans MC, Kay RG, Dowman M, Wattie D, Reid IR. Effect of vertical banded gastroplasty on bone and mineral metabolism in obese subjects. **Brit J Surg** 1996; 83:1468-1472.

78. Grey AB, Stapleton JP, Evans MC, Reid IR. Accelerated bone loss in postmenopausal women with mild primary hyperparathyroidism. **Clin Endocrinol** 1996; 44:697-702.
79. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of estrogen/progestin therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism. **Ann Int Med** 1996; 125: 360-368.
80. Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy TF, Kotowicz MA, Murphy WA, Swan Yeap, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. **Am J Med** 1996; 101:341-348.
81. Cornish J, Callon K, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. **Calcif Tissue Int** 1996; 59:492-495.
82. Reid IR. Has improved nutrition contributed to the hip fracture epidemic? **Mol Cell Endocrinology** 1996; 123:123-125.
83. Orr-Walker B, Wattie DJ, Evans MC, Reid IR. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in postmenopausal osteoporosis. **Clin Endocrinol** 1997; 46: 87-92.
84. Cornish J, Callon K, Nicholson GC, Reid IR. Parathyroid hormone related protein-(107-139) inhibits bone resorption in vivo. **Endocrinology** 1997; 138:1299-1304.
85. Reid IR. Use of testosterone for treatment of steroid-induced osteoporosis in older men. **Clin Geriatr** 1997; 5:27-33.
86. Chin K, Evans MC, Cornish J, Cundy T, Reid IR. Differences in hip axis and femoral neck length in premenopausal women of Polynesian, Asian and European origin. **Osteoporosis Int** 1997; 7:344-347
87. Grey AB, Evans MC, Kyle C, Reid IR. The anti-oestrogen tamoxifen produces haemodilution in normal postmenopausal women. **J Int Med** 1997; 242: 383-388.
88. Cornish J, Callon KE, Edgar SG, Reid IR. Leukemia inhibitory factor is mitogenic to osteoblasts. **Bone** 1997; 21: 243-247
89. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Reid IR. Premature hair graying and bone mineral density. **J Clin Endocrinol Metab** 1997; 82: 3580-3583.
90. Cornish J, Callon KE, Coy DH, Jiang N-Y, Xiao L, Cooper GJS, Reid IR. Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. **Am J Physiol** 1997; 36:E1113-E1120
91. Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Coy DH, Cooper GJS, Reid IR.

Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. **Am J Physiol** 1998; 274:E827-E833.

92. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy TF, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. **Clin Endocrinol** 1998; 49:615-618.
93. Norton R, Campbell AJ, Reid IR, Butler M, Currie R, Robinson E, Gray H. Residential status and risk of hip fracture. **Age Ageing** 1999; 28:135-139.
94. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. **Obstet Gynecol** 1998; 92:569-573.
95. Cornish J, Callon KE, King AR, Cooper GJS, Reid IR. Systemic administration of amylin increases bone mass, linear growth and adiposity in adult male mice. **Am J Physiol (Endocrinol Metab)** 1998; 38:E694-E699
96. Sharples K, Fleming TR, MacMahon S, Moore A, Reid IR, Scoggins B. Monitoring clinical trials. **NZ Med J** 1998; 111: 322-325.
97. Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. Stimulation of osteoblast proliferation by COOH-terminal fragments of parathyroid hormone-related protein. **J Bone Mineral Res** 1999; 14: 915-922.
98. Orr-Walker BJ, Horne AM, Evans MC, Grey AB, Murray MAF, McNeil AR, Reid IR. Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women. **J Clin Endocrinol Metab** 1999; 84: 1997-2001.
99. Cornish J, Callon KE, Lin C, Xiao CL, Gamble GD, Cooper GJS, Reid IR. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. **J Bone Mineral Res** 1999; 14: 1302-1309.
100. Cornish J, Callon KE, Lin C, Xiao CL, Mulvey TB, Cooper GJS, Reid IR. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. **Am J Physiol** 1999; 277: E779-E785.
101. Braatvedt GD, Joyce M, Evans M, Clearwater J, Reid IR. Bone mineral density in patients with treated Addison's disease. **Osteoporos Int** 1999; 10:435-440.
102. Neal BC, Rodgers A, Clark T, Gray H, Reid IR, Dunn L, MacMahon SW. A systematic survey of 13 randomized trials of nonsteroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. **Acta Orthopaed Scand** 2000; 71: 122-128
103. Neal BC, Rodgers A, Gray H, Clark T, Beaumonts DD, House T, Douglas JE, Reid IR, MacMahon SW. No effect of low-dose aspirin for the prevention of heterotopic

bone formation after total hip replacement - A randomized trial of 2,649 patients.  
**Acta Orthopaed Scand** 2000; 71: 129-134

104. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR. The effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism - 4 year follow-up and comparison with normal postmenopausal women. **Arch Int Med** 2000; 160:2161-2166
105. Cardon LR, Garner C, Bennett ST, MacKay IJ, Edwards RM, Cornish J, Hedge M, Murray MAF, Reid IR, Cundy T. Evidence for a major gene for bone mineral density in idiopathic osteoporotic families. **J Bone Mineral Res** 2000; 15:1132-7.
106. Cornish J, Callon KE, Gasser JA, Bava U, Gardiner EM, Coy DH, Cooper GJS, Reid IR. Systemic administration of a novel octapeptide, amylin-(1-8), increases bone volume in male mice. **Am J Physiol** 2000; 279:E730-E735.
107. Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MAF, McNeil AR, Gamble GD. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women - a randomized controlled trial. **Am J Med** 2000; 109:362-370.
108. Blok BH, Grant CG, McNeil AR, Reid IR. Characteristics of children with florid vitamin D deficient rickets in the Auckland region in 1998. **NZ Med J** 2000; 113:374-376
109. Wu F, Ames R, Evans MC, France JT, Reid IR. Determinants of sex hormone-binding globulin in normal postmenopausal women. **Clin Endocrinol** 2001; 54:81-87
110. Grey AB, Banovic T, Naot D, Hill B, Reid IR, Cornish J. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G<sub>i</sub> proteins and protein kinase C but not p42/p44 MAP kinases. **Endocrinology** 2001; 142:1098-1106
111. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe DN on behalf of the LIPID Study Group. Effect of pravastatin on fracture frequency in the Lipid study: secondary analysis of a randomised controlled trial. **Lancet** 2001; 357:509-512
112. Norton R, Galgali G, Campbell AJ, Reid IR, Robinson E, Butler M, Gray H. Is physical activity protective against hip fracture among frail older people? **Age Ageing** 2001; 30:262-264
113. Naot D, Callon KE, Grey AB, Cooper GJS, Reid IR, Cornish J. A potential role for adrenomedullin as a local regulator of bone growth. **Endocrinology** 2001; 142:1849-1857
114. Wu F, Mason B, Horne A, Ames R, Clearwater J, Liu M, Evans MC, Gamble GD, Reid IR. Fractures between ages 20 and 50 years increase women's risk of

subsequent fractures. **Arch Int Med** 2002; 162:33-36

115. Cornish J, Callon KE, Bava U, Coy DH, Mulvey TB, Murray MAF, Cooper GJS, Reid IR. Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice. **J Endocrinol** 2001; 170:251-257
116. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJS, Reid IR. Effects of calcitonin, amylin and calcitonin gene-related peptide on osteoclast development. **Bone** 2001; 29:162-168
117. Reid IR, Mason B, Horne A, Ames R, Clearwater J, Bava U, Orr-Walker B, Wu F, Evans MC, Gamble GD. Effects of calcium supplementation on serum lipids in normal older women - a randomized controlled trial. **Am J Med** 2002; 112:343-347
118. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al. Intravenous zoledronic acid in postmenopausal osteoporosis - dose and dose-interval effects. **N Engl J Med** 2002; 346:653-661
119. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone contraception. **Amer J Obstet Gynecol** 2002; 186: 978-983
120. Wu F, Ames R, Clearwater J, Evans MC, Gamble G, Reid IR. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women - including effect of hormone replacement therapy. **Clin Endocrinol** 2002; 56:703-711
121. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love D, Seidel J, Fawkner M, Banovic T, Callon K, Grey A, Reid IR, Middleton-Hardie C, Cornish J. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. **Human Mol Genetics** 2002; 11: 2119-2127
122. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Meyers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. **J Endocrinol** 2002;175:405-415
123. Grey A, Chen Q, Callon K, Xu X, Reid IR, Cornish J. The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving Gi proteins and PI-3 kinase. **Endocrinology** 2002;143:4755-4763
124. Cundy T, Ames R, Horne A, Roberts H, Gamble G, Reid IR. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone with low bone density. **J Clin Endocrinol Metab** 88:78-81, 2003

125. Young R, Wu F, Van de Water N, Ames R, Gamble G, Reid IR. Calcium sensing receptor gene A986S polymorphism and responsiveness to calcium supplementation in postmenopausal women. **J Clin Endocrinol Metab** 88:697-700, 2003
126. Latham NK, Anderson CS, Reid IR. Effects of Vitamin D supplementation on strength, physical performance and falls in older persons. A systematic review. **J Am Geriatr Soc** 51:1219-1226, 2003
127. Cornish J, Gillespie MT, Callon KE, Horwood NJ, Moseley JM, Reid IR. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. **Endocrinology** 144:1194-1201, 2003
128. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in normal postmenopausal women. **Arch Int Med** 164:871-879, 2004
129. Cornish J, Callon KE, Mountjoy KG, Bava U, Lin J-M, Myers DE, Naot D, Reid IR.  $\alpha$ -Melanocyte stimulating hormone ( $\alpha$ -MSH) is a novel regulator of bone. **Amer J Physiol** 2003; 284: E1181-E1190.
130. Dissanayake AM, Wilson J, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection by whole body magnetic resonance imaging. **Int Med J** 2003; 33:615-616
131. Wu F, Staykova T, Horne A, Clearwater J, Ames R, Mason B, Orr-Walker B, Gamble G, Scott M, Reid IR. Efficacy of an oral 10-day course of high dose calciferol in correcting vitamin D deficiency. **NZ Med J** 8 August 2003; 116(1179): U536, pp1-5
132. Lucas JA, Lucas PR, Vogel S, Gamble GD, Evans MC, Reid IR. The effect of sub-elite competitive running on bone density, body composition and sexual maturity of adolescent females. **Osteoporos Int** 2003; 14: 848-856.
133. Grey AB, Xu X, Hill B, Watson M, Callon K, Reid IR, Cornish J. Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate. **Calcif Tissue Int** 2004;74:542-550
134. Orr-Walker, B, Evans MC, Reid IR, Cundy T. Increased abdominal fat in young women of Indian origin. **Diabetes Res Clin Prac** (in press)
135. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. **Bone** 2004; 35:224-230
136. Cornish J, Grey AB, Callon KE, Naot D, Hill BL, Lin CQX, Balchin LM, Reid IR.

Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. **Biochem Biophys Rec Comm** 2004; 318: 240–246.

137 Whalley GA, Doughty RN, Gamble GD, Oxenham HC, Walsh HJ, Reid IR, Baldi JC. Association of fat free mass and training status with left ventricular size and mass in endurance-trained athletes. **J Amer Coll Cardiol** 2004; 44:892–896

138 Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR. The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. **Bone** 2004; 35: 766– 770

139 Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, Watson M, Lin J, Tong PC, Chen Q, Chan VA, Reid HE, Fazzalari N, Baker HM, Baker EN, Haggarty NW, Grey AB, Reid IR. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. **Endocrinology** 2004; 145:4366-4374

140 Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, Ross J, Naot D, Reid IR, Cornish J. The low density lipoprotein-receptor-related protein 1 (LRP1) is a mitogenic receptor for lactoferrin in osteoblastic cells. **Mol Endocrinol** 2004; 18: 2268-2278

141 Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC.  $\beta$ -blocker use, bone mineral density and fractures in the Study of Osteoporotic Fractures. **J Bone Mineral Res** 20: 613-618, 2005

142 Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. **J Clin Endocrinol Metab** 2005; 90:1525-1530

143 Grey AB, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. **J Clin Endocrinol Metab** 2005;90 2122-2126

144 Lucas JA, Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR. Determinants of vitamin D status in older women living in a subtropical climate **Osteoporos Int** (in press)

145 Reid IR, Horne A, Mason B, Ames R, Bava U, Gamble GD. Effects of calcium supplementation on body weight and blood pressure in normal older women - a randomized controlled trial. **J Clin Endocrinol Metab** 90: 3824-3829, 2005

146 Pavlov L, Gamble GD, Reid IR. Comparison of dual-energy x-ray absorptiometry and conventional radiography for the detection of vertebral fractures. **J Clin Densitometry** (in press)

147 Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D. A single infusion of

zoledronic acid improves remission rates in Paget's disease: a randomized controlled comparison with risedronate. **N Engl J Med** (in press)

148 Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, Davidson JS, Grey AB. Effects of a  $\beta$ -blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. **J Clin Endocrinol Metab** (in press)

#### Letters Reporting Novel Data

1. Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. **Lancet** 1988; ii: 1144.
2. Ford DJ, Reid IR. Hypercalcaemia associated with viral hepatitis. **Lancet** 1990; 336: 181.
3. Grey AB, Reid IR. Body weight and hyperparathyroidism. **Ann Int Med** 1995; 123:732.
4. Reid IR. Calcium supplements and nail quality. **N Engl J Med** 2000; 343:1817
5. Wu F, Orr-Walker B, Reid IR. Clinical limitations of bone-specific alkaline phosphatase assays. **Ann Clin Biochem** 2001;38:572.
6. Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial - secondary analysis of a randomized controlled trial. **Bone** (in press)

#### Editorials

1. Reid IR. Editorial, Steroid osteoporosis. **Calcif Tissue Int** 1989; 45: 63-67.
2. Reid IR. Commentary - The investigation of hypercalcaemia. **Clin Endocrinol** 1994; 41:405-406.
3. Reid IR. Invited commentary - Post-gastrectomy bone disease. **World J Surg** 1995; 19:601-602.
4. Reid IR. Editorial: Racial effects on body composition - it's not all black and white. **J Lab Clin Med** 1997; 129:281-2.
5. Reid IR. Editorial - Prevention of steroid osteoporosis. **N Engl J Med** 1997; 337: 420-421.
6. Reid IR. Glucocorticoid effects on bone **J Clin Endocrinol Metab** 1998; 83: 1860-1862

7. Reid IR. Time to end steroid-induced fractures. **Arch Dermatol** 2001; 137:493-4.
8. Reid IR. Prevention of hip fractures with risedronate. **IBMS BoneKEy** 2001; 10.1138/ibmske;2001015.
9. Reid IR. Anti-Fracture Efficacy of Hormone Replacement Therapy **IBMS BoneKEy** 2001; 10.1138/ibmske;2001035
10. Reid IR. The skeleton in pregnancy and lactation. **Int Med J** 2002; 32:433-434
11. Reid IR. Risks and benefits of hormone replacement therapy (HRT). **Premec Bulletin** 109, 2002
12. Reid IR. Calcitriol and alfacalcidol in the management of osteoporosis. **Premec Bulletin** 110, 2003
13. Reid IR. Leptin deficiency – lessons in regional differences in the regulation of bone mass. **Bone** 2004; 34:369-371
14. Reid IR. Long term use of alendronate. **IBMS BoneKEy** 2005 Jan 1 doi:10.1138/20050144

#### Reviews in Journals

1. Nordin BEC, Fraser TRC, Eisman J, Reid IR, Clifton-Bligh P. Osteoporosis. **New Ethicals** April 1985; 29-48.
2. Reid IR. The role of dietary calcium in the pathogenesis and treatment of osteoporosis. **NZ Med J** 1989; 102: 532-3.
3. Reid IR. Postmenopausal osteoporosis: prevention and treatment. **New Ethicals** 1990; 27: 71-78.
4. Martin TJ, Allan EH, Evely RS, Reid IR. Leukaemia inhibitory factor and bone cell function. In: Bock GR, Widdows K eds. Polyfunctional Cytokines: IL-6 and LIF. Wiley, Chichester (**Ciba Foundation Symposium** 167), 1992;141-155.
5. Reid IR. Osteoporosis. **Proc Nutr Soc NZ** 1992; 17:194-197.
6. Reid IR. Steroid osteoporosis. **Osteoporosis Int** 1993; 3(suppl 1):S144-146.
7. Reid IR, Grey AB. Corticosteroid osteoporosis. **Bailliere's Clinical Rheumatology** 1993; 7:573-587.
8. Reid IR, Tregonning GD. Osteoporosis. **Patient Management** 1993;22(9):45-47.
9. Reid IR. Steroid osteoporosis. **Spine: State of the Art Reviews** 1994; 8:111-131.

10. Reid IR, Veale AG, France JT. Glucocorticoid osteoporosis. **J Asthma** 1994; 31:7-18.
11. Reid IR. Factors related to bone density in normal women-an important role for fat mass. **Eur J Med Updating** 1994.
12. Reid IR, Cundy TF. Regional focus series: Research in New Zealand. Osteoporosis research in Auckland. **Clin Science** 1995; 88:12-14.
13. Cornish J, Callon KE, Cooper GJS, Reid IR. Amylin stimulates bone growth in experimental animals. **NZ Bioscience** Feb 1995, 17-18.
14. Reid IR. Management of painful bone conditions. **New Ethicals** 1995; 32:9-13.
15. Reid IR. Treatment and prevention of osteoporosis. **New Ethicals** 1996; 33:27-33.
16. Reid IR. Therapy of osteoporosis: calcium, vitamin D and exercise. **Am J Med Sci** 1996; 312:278-286.
17. Reid IR. Hormone replacement therapy. **Patient Management** 1997; 26: 35-36.
18. Reid IR. Establishing healthy bones in the young. **Aust Family Physician** 1997; 26: 132-134.
19. Reid IR. Glucocorticoid osteoporosis - mechanisms and management. **Eur J Endocrinol** 1997; 137:209-217
20. Reid IR. When and how to treat steroid-induced osteoporosis. **Current Opinion in Endocrinology and Diabetes** 1997; 4:204-208.
21. Reid IR. Investigations in osteoporosis. **Patient Management** 1997; 26: 23-26.
22. Reid IR. Steroid-induced osteoporosis. **Osteoporosis Int** 1997; 7 (suppl 3): 213 - 216.
23. Reid IR. The role of calcium in the prevention and treatment of osteoporosis. **The Endocrinologist** 1997; 7: 294-299
24. O'Neill S, Eisman JA, Glasziou P, Kent GN, Murkies A, Owen JW, Reid IR, Sambrook P, Scharer M, Smith M, Stenmark J. The prevention and management of osteoporosis. Australian National Consensus Conference 1996. **Med J Australia** 1997; 167 suppl.
25. Reid IR. Osteoporosis: role of calcium and vitamin D. **Endocrinol Metab Clin Nth Amer** 1998; 27:389-398
26. Reid IR. Osteoporosis - - emerging consensus. **Aust NZ J Med** 1997; 27:643-647

27. Reid IR. Osteoporosis management. **New Ethicals** 1997; 26 (11): 33-34.
28. Reid IR. Osteoporosis. **New Ethicals J** 1998; 1: 25.
29. Reid IR. Glucocorticoid-induced osteoporosis: assessment and treatment. **J Clin Densitometry** 1998; 1:65-73.
30. Cornish J, Reid IR. Skeletal effects of amylin and related peptides. **The Endocrinologist** 1999; 9:183-189.
31. Reid IR. Pharmacological management of osteoporosis in postmenopausal women: a comparative review. **Drugs and Aging** 1999; 15: 349-363.
32. Reid IR. Glucocorticoid osteoporosis. **J Intensive Care Med** 1999; 14:231-242.
33. Reid IR, Siris E. Alendronate in the treatment of Paget's disease of bone. **Int J Clin Prac Suppl** 101: 62-66
34. Reid IR. New technology - bone densitometry. **NZ Family Physician** 1999; 26:32-35.
35. Genant HK, Cooper C, Poor G, Reid IR, et al. Interim Report of the World Health Organisation Task-Force on Osteoporosis. **Osteoporosis Int** 1999; 10:259-264.
36. Reid IR et al. Guidelines for the management of postmenopausal osteoporosis. **NZ Family Physician** 1999; 26:15.
37. Reid IR. Drug treatment in postmenopausal osteoporosis. **New Ethicals Journal** 2000; 3:43-51
38. Reid IR. How to treat osteoporosis. **NZ Doctor** Sept 13, 2000; pp17-21
39. Wu F, Reid IR. Calcitonin in the prevention and treatment of glucocorticoid-induced osteoporosis. **Clin Exp Rheumatol** 2000; 18 (suppl 21): S53-S56
40. Reid IR. Osteoporosis in New Zealand. **Clinical Calcium** 2001; 11:115-7
41. Reid IR. Preventing glucocorticoid-induced osteoporosis. **Zeitschrift Rheumatol** 2000; 59 suppl 2:97-102
42. Reid IR. Glucocorticoid osteoporosis. **Bailliere's Clin Endocrinol Metab** 2000; 14:279-298
43. Reid IR. Osteoporosis - non-HRT treatments. **Rev Gynaecol Prac** 2002; 2:48-53
44. Reid IR. Terapia de reemplazo con estrogen  
<http://www.siicsalud.com/dato/dat022/01212028.htm>

45. Cornish J, Reid IR. Effects of amylin and adrenomedullin on the skeleton. **J Musculoskeletal Neuron Interaction** 2001; 2:15-24
46. Reid IR. A new receptor to turn on bone growth. **NZ Med J** 2002; 115: 169-170.
47. Reid IR. Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. **Expert Opinion Drug Safety** 2002; 1:93-107
48. Sambrook PN, Seeman E, Phillips SR, Ebeling PR, Bass SL, Bennell KL, Cameron ID, Cowell CT, Davis SR, Diamond T, Eisman JA, Flicker L, Ferris LR, Singh MAF, Glasziou PP, Hooper MJ, Jones G, Lord SR, March LM, O'Neill SM, Pocock NA, Prince RL, Reid IR, Sanders KM. Preventing osteoporosis: Outcomes of the Australian Fracture Prevention Summit - Cosponsored by Osteoporosis Australia and the National Prescribing Service. **Med J Aust.** 176(Suppl S):S1-S16, 2002.
49. Reid IR. Relationships among body mass, its components, and bone. **IBMS BoneKEy** 2002; 10.1138/ibmske;2002055, and **Bone** 31: 547-555
50. Cornish J, Naot D, Reid IR. Adrenomedullin – a regulator of bone formation. **Regulatory Peptides** 112:79-86, 2003
51. Reid IR, Cornish J. Direct actions of leptin on bone remodeling. **Calcif Tissue Int** 74:313-316, 2004
52. Reid IR. Cardiovascular benefits of calcium supplementation in postmenopausal women: potential pharmacoeconomic implications. **Drugs Aging** 21:7-17, 2004
53. Reid IR. Bisphosphonates: new indications and methods of administration. **Curr Opin Rheumatol** 15:458-463, 2003
54. Reid IR. Steroid osteoporosis. **Adv Osteoporotic Fracture Management** 2: 79-87, 2003
55. Reid IR. How to treat osteoporosis. **NZ Doctor** Aug 27, 2003, pp25-31
56. Reid IR, Grey AB. Treatment of osteoporosis. **Disorders of Bone & Mineral Metabolism Updates** 1:1-14, 2004
57. Reid IR. Paget's disease of bone. **Pharmacy Today** (in press)
58. Grey AB, Reid IR. Emerging and potential therapies for osteoporosis. **Expert Opinion on Investigational Drugs** 14:265-278, 2005.
59. Cornish J, Grey AB, Naot D, Palmano KP, Haggarty NW, Callon KE, Reid IR. Lactoferrin and bone – an overview of recent progress. **Austral J Dairy Technol** 60: 53-57, 2005.

58 Naot D, Grey AB, Reid IR, Cornish J. Lactoferrin – a novel bone growth factor. **Clin Med Res** 3:93-101, 2005

### Books

1. Kolbe J, Reid I. (eds.). **North-Nanson Clinical Manual**. University of Auckland 1989; 114 p.
2. Reid IR (ed). **Metabolic Bone Disease. Bailliere's Clinical Endocrinology and Metabolism**. Bailliere Tindall, London, 1997.
3. Reid IR (ed). **Osteoporosis Management**, Adis Press, Auckland, 2000.
4. WHO Scientific Group (IR Reid rapporteur). **Prevention and Management of Osteoporosis**. World Health Organization, Geneva, 2003
5. Reid IR (ed). **Clinical Reviews in Bone and Mineral Metabolism** vol 1. Humana Press, Totowa NJ, 2002.

### Sections in Books

1. Reid IR, Civitelli R, Avioli LV, Hruska KA. Evidence for novel second messengers of PTH in osteoblast-like cells. In, Christiansen et al (eds.), **Osteoporosis 1987**, Kobenhavn, Osteopress ApS, 1987, pp. 237-239.
2. Reid IR, King AR, Stewart AW, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis. In, Christiansen et al (eds.), **Osteoporosis 1987**, Kobenhavn, Osteopress ApS, 1987, pp. 1016-1020.
3. Reid IR. Osteoporosis. In: Speight TM (ed), **The Disease Index**, Auckland, Medical Publishing, 1989, p328-329.
4. Reid IR. Effects of glucocorticoids on bone mineral metabolism, growth and fracture rates. In: Christiansen C, Krane SM (eds) **Advances in Corticosteroids**. Langhorne, Adis, 1993.
5. Reid IR. Vitamin D and its metabolites in the management of osteoporosis. In: Marcus R, Feldman D, Kelsey J eds. **Osteoporosis**. Academic Press, San Diego, 1996.
6. Reid IR. Bone homeostasis. In: Gluckman PD, Heymann MA (eds). **Scientific Basis of Pediatric and Perinatal Medicine**, 2nd ed. Arnold, London, 1996.
7. Cundy T, Reid IR. Calcium, magnesium and phosphate. In: Marshall W, Bangert S (eds), **Clinical Biochemistry**. London, Churchill Livingstone, 1995.
8. Cundy T, Reid IR. Metabolic bone disease. In: Marshall W, Bangert S (eds),

**Clinical Biochemistry.** London, Churchill Livingstone, 1995.

9. Reid IR, Cornish J. Amylin and CGRP. In Bilezikian JP, Raisz LG, Rodan GA (eds), **Principles of Bone Biology.** San Diego, Academic Press, 1996.
10. Reid IR. Pamidronate therapy for Paget's disease of bone. In: **Bisphosphonates - Improved Treatment of Osteolysis in Malignant and Non-Malignant Indications** Possinger K, Ziegler R, eds. **Excerpta Oncologica Ciba.** Ciba-Geigy Verlag, Wehr, 1996.
11. Reid IR. Novel bone forming agents. In Zaidi M, **Molecular and Cellular Biology of Bone.** Greenwich, JAI Press, 1999.
12. Reid IR. The management of osteoporosis. **Bailliere's Clinical Endocrinology and Metabolism.** 1997; 11:63-81.
13. Reid IR. Glucocorticoid osteoporosis and other forms of secondary osteoporosis. In: Meunier PJ (ed), **Osteoporosis: Diagnosis and Management.** London, Martin Dunitz, 1998.
14. Reid IR. Future therapies. In Geusens P (ed), **Osteoporosis in Clinical Practice** 1998, pp171-173.
15. Reid IR. Glucocorticoids and osteoporosis. In Orwoll E (ed), **Osteoporosis in Men: the Effects of Gender on Skeletal Health,** 1999
16. Reid IR. Steroid-induced osteoporosis. In: Seibel M, Robins S, Bilezikian J (eds). **Dynamics of Bone and Cartilage Metabolism,** 1999
17. Reid IR. Menopause. In: Favus MJ (ed). **Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism 4<sup>th</sup> ed,** American Society for Bone and Mineral Research, 1999.
18. Reid IR. Corticosteroid-induced osteoporosis. In: Hosking D, Ringe J (eds). **Treatment of Metabolic Bone Disease,** 2000
19. Cundy T, Roberts H, Reid IR. Depot medroxyprogesterone acetate contraception and reduced bone density. In: Salamonsen LA (ed). **Hormones and Women's Health,** Harwood Academic Press, 2000.
20. Reid IR. Vitamin D and its metabolites in the management of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds), **Osteoporosis,** 2nd ed, Academic Press, San Diego, 2000.
21. Reid IR. Clinical aspects of the use of vitamin D and its metabolites in osteoporosis. In: Orwoll E, Bliziotes M (eds) **Osteoporosis: Scientific Principles and Clinical Practice,** Humana, Totowa, pp293-308, 2002.

22. Reid IR. Treatment of osteoporosis. In: Coe F, Favus M (eds) **Disorders of Bone and Mineral Metabolism**, 2nd ed Lippincott, Philadelphia, pp 831-846, 2002.
23. Reid IR, Cornish J. Amylin and CGRP. In Bilezikian JP, Raisz LG, Rodan GA (eds), **Principles of Bone Biology**, 2nd ed. San Diego, Academic Press pp 641-654, 2002.
24. Reid IR. Glucocorticoid-Induced Osteoporosis. In: Cummings SR, Cosman F, Jamal S, eds. **Osteoporosis: Prevention, Diagnosis and Management**, Philadelphia, American College of Physicians, pp 223-238, 2002.
25. Reid IR. Future therapies. In Geusens P (ed), **Osteoporosis in Clinical Practice**, 2nd ed, Springer-Verlag London, 2004
26. Reid IR. Drug treatment in postmenopausal osteoporosis. In: **Australasian Women's Health**, Auckland, Adis, pp 127-134, 2002.
27. Reid IR. Vitamin D. In Martini L (ed), **Encyclopedia of Endocrinology**, San Diego, Academic Press, vol 4, pp 657 - 665, 2004 .
28. Reid IR. Vitamin D and fracture prevention. In: New SA (ed) **Nutritional Aspects of Bone Health**, London, Leatherhead, 2003 .
29. Reid IR. Menopause. In: Favus MJ (ed). **Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism 5<sup>th</sup> ed**, American Society for Bone and Mineral Research, 2003.
30. Reid IR. Management: Established osteoporosis in organ transplant recipients. In: Shane E, Compston J (eds). **Bone Disease of Organ Transplantation**, San Diego, Academic, 2005
31. Reid IR. Steroid-induced osteoporosis. In: Seibel M, Robins S, Bilezikian J (eds). **Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications**, 2<sup>nd</sup> ed, San Diego, Elsevier (in press)
32. Reid IR. Bisphosphonates in the prevention and treatment of postmenopausal osteoporosis. In: Lane NE, Sambrook PN (eds). **Osteoporosis and Osteoporosis of Rheumatic Diseases**. Philadelphia, Elsevier (in press)

Other Letters, Book Reviews, Other Publications

1. Reid IR. Serum testosterone levels during chronic glucocorticoid therapy. **Ann Int Med** 1987; 106: 639.
2. Reid IR, Ibbertson HK. Corticosteroids and osteoporosis. **Aust NZ J Med** 1987; 17: 611-612.

3. Reid IR. Hyperoxaluria in phosphate-treated hypophosphataemic rickets. **Lancet** 1990; 336: 378.
4. Cundy TF, Reid IR, Roberts H. DMPA and bone density. **BMJ** 1991; 303:468.
5. Reid IR. Osteoporosis management. **NZ Med J** 1992; 105: 20-21.
6. Reid IR. Fluoridation and fractures. **NZ Med J** 1993; 106:392.
7. Reid IR. Calcium supplementation in postmenopausal women. **N Engl J Med** 1993; 329:279.
8. Reid IR. Hormone replacement therapy. **NZ Med J** 1994; 107: 138.
9. Reid IR, Cundy TF, Ibbertson HK, King AR. Osteomalacia after pamidronate for Paget's disease. **Lancet** 1994; 343:855.
10. Cundy TF, Reid IR. Depot medroxyprogesterone and bone density. **BMJ** 1994; 308:1567-1568.
11. Grey AB, Evans MC, Reid IR. Bone density and body weight in hyperparathyroidism. **Ann Int Med** 1995; 122:801.
12. Cundy T, Reid IR. Short-term effects of high dose oral medroxyprogesterone on bone density in premenopausal women - response. **J Clin Endocrinol Metab** 1996; 81: 4501.
13. Reid IR. Book Review - "Textbook of Osteoporosis". **NZ Med J** (in press).
14. Cundy T, Reid IR. Bone loss and depot medroxyprogesterone. **Am J Obstet Gynecol** 1997; 176:1116-1117.
15. Reid IR. Bones of a certain age. **Lancet** 356:82
16. Reid IR. Vitamin D concentrations in tuberculosis. **Lancet** 356:74 (letter)
17. Reid IR. **Medicines Information Bulletin 79 – Prevention and Treatment of Glucocorticoid-Induced Osteoporosis**. Preferred Medicines Centre, Wellington. 1999
18. Reid IR. Handbook of Dairy Foods and Nutrition **J Bone Mineral Res** 2000; 15:2524
19. Reid IR. **Medicines Information Bulletin - Osteoporosis**. Preferred Medicines Centre, Wellington. 2001
20. Reid IR. Reply to: What role would thiazide diuretics have in the prevention of postmenopausal osteoporosis? **Am J Med** 2001; 111:162

21. Reid IR, Hague W. Statins and fractures. **Lancet** 2001; 357:1887-1888 (letter).
22. Reid IR, Burckhardt P, Brown JP. Bisphosphonates and osteoporosis. **N Engl J Med** 2002; 346: 2089.
23. Reid IR. **Medicines Information Bulletin 109 – Risks and Benefits of Hormone Replacement Therapy**. Preferred Medicines Centre, Wellington. 2002
24. Reid IR. Effects of calcium supplementation on serum lipid levels in postmenopausal women - reply. **Am J Med** 2003;114:621 (letter)
25. Blumsohn A, Faccio R, Jiang Y, Karsenty G, Klein RF, Kotowicz MA, Reid IR, Robey PG, Seeman E, Strewler GJ. Meeting Report from the 25th Annual Meeting of the American Society for Bone and Mineral Research. IBMS BoneKEy 2003 Dec 1810.1138/ibmske;20030112v1  
Url: <http://www.bonekey-ibms.org/cgi/content/full/ibmske;20030112>